George A. Scangos
Net Worth
Last updated:
What is George A. Scangos net worth?
The estimated net worth of Dr. George A. Scangos is at least $6,366,813 as of 26 Feb 2024. He owns shares worth $491,502 as insider, has earned $2,890,671 from insider trading and has received compensation worth at least $2,984,640 in Vir Biotechnology, Inc..
What is the salary of George A. Scangos?
Dr. George A. Scangos salary is $994,880 per year as Pres, Chief Executive Officer & Director in Vir Biotechnology, Inc..
How old is George A. Scangos?
Dr. George A. Scangos is 77 years old, born in 1948.
What stocks does George A. Scangos currently own?
As insider, Dr. George A. Scangos owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | Pres, Chief Executive Officer & Director | 112,989 | $4.35 | $491,502 |
What does Vir Biotechnology, Inc. do?
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
George A. Scangos insider trading
Vir Biotechnology, Inc.
Dr. George A. Scangos has made 12 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 17,722 units of VIR stock worth $206,514 on 26 Feb 2024.
The largest trade he's ever made was exercising 17,726 units of VIR stock on 18 Feb 2022. As of 26 Feb 2024 he still owns at least 112,989 units of VIR stock.
Vir Biotechnology key executives
Vir Biotechnology, Inc. executives and other stock owners filed with the SEC:
- Dr. George A. Scangos (77) Pres, Chief Executive Officer & Director
- Dr. Herbert W. Virgin IV (69) Executive Vice President of Research & Chief Scientific Officer
- Mr. Howard Horn (47) Chief Financial Officer & Sec.
- Mr. Steven J. Rice (65) Chief Admin. Officer